iRhythm Technologies Inc (IRTC)

Business Description

iRhythm Technologies, Inc. (IRTC) is a healthcare technology company specializing in global ambulatory cardiac monitoring. The company provides innovative diagnostic services through its Zio platform, which includes wearable devices and data analytics to monitor and diagnose cardiac arrhythmias. IRTC's operations focus on delivering clinically validated solutions to improve patient outcomes and streamline healthcare workflows.

Zio Services - Offers wearable cardiac monitoring devices, including the Zio XT and Zio Monitor, designed to detect and diagnose arrhythmias through continuous monitoring and advanced data analytics.

Key Metrics

View all financials →

Leadership

Name	Position	External Roles	Short Bio
Quentin Blackford ExecutiveBoard	President, Chief Executive Officer, Director	Board Member at Alphatec Holdings, Inc. and Paragon 28, Inc.	Joined IRTC in October 2021. Former COO at Dexcom, CFO at NuVasive, and finance leader at Zimmer Holdings. Holds dual B.S. degrees in Accounting and Business Administration. Certified Public Accountant (inactive).	View Report →
Chad Patterson Executive	Chief Commercial Officer	None	Joined IRTC in July 2022. Former EVP and CMO at Dexcom. Played a key role in Dexcom's revenue growth and global expansion. Holds an MBA from USC and a B.A. from Gonzaga University.
Daniel Wilson Executive	Chief Financial Officer	None	Joined IRTC in June 2019. Previously EVP of Corporate Development and Investor Relations. Former healthcare investment banker at J.P. Morgan and business development leader at Penumbra, Inc..
Mervin Smith Executive	EVP of Business Operations	None	Joined IRTC in July 2023. Former VP & GM at Zimmer Biomet. Holds an MBA from Ball State University and a B.S. in Accounting from the University of Pittsburgh.
Minang Turakhia, M.D. Executive	Chief Medical Officer, Chief Scientific Officer, EVP of Product Innovation	Professor of Medicine (on leave) at Stanford University School of Medicine	Joined IRTC in June 2022. Renowned cardiologist and researcher. Played a key role in clinical research and product launches at IRTC. Holds an M.D. from Stanford University.
Patrick Murphy Executive	Chief Business Officer and Chief Legal Officer	None	Joined IRTC in November 2021. Former EVP and CLO at Dexcom. Extensive legal and corporate finance experience. Holds a J.D. from St. Louis University School of Law.
Sumi Shrishrimal Executive	Chief Risk Officer	None	Joined IRTC in May 2022. Former Chief Risk Officer at Dexcom and VP of Internal Audit at NuVasive. Holds a B.A. in Accounting and Information Systems from the University of Mumbai.
Abhijit Y. Talwalkar Board	Chairman of the Board	Board Member at AMD, TE Connectivity, and Lam Research; Chairman at Friends of the Children (Bay Area Chapter)	Chairman of IRTC since May 2016. Former CEO of LSI Corporation and senior leader at Intel. Holds a B.S. in Electrical Engineering from Oregon State University.
Brian Yoor Board	Director	Chairman at Covira Surgical; Audit Committee Chair at Confluent Medical	Director at IRTC since June 2023. Former CFO at Abbott Laboratories. Holds a B.B.A. in Accounting from the University of Toledo.
Bruce G. Bodaken Board	Director	None	Director at IRTC since July 2017. Former CEO of Blue Shield of California. Extensive experience in healthcare leadership.
C. Noel Bairey Merz, M.D. Board	Director	Medical Director at Cedars-Sinai Medical Center; Professor at UCLA	Director at IRTC since April 2018. Renowned cardiologist and researcher. Holds an M.D. from Harvard Medical School and a B.A. from the University of Chicago.
Karen Ling Board	Director	None	Director at IRTC since November 2021. Former EVP and Chief Human Resources Officer at AIG. Extensive experience in HR and corporate governance.
Mark J. Rubash Board	Director	Chairman of Intuitive Foundation; Board Member at Intuitive Surgical	Director at IRTC since March 2016. Former CFO at Shutterfly and senior finance leader at eBay. Holds a B.S. in Accounting from California State University, Sacramento.

Questions to Ask Management

Given that international markets are contributing only 1% to growth in 2025 and are still in early stages, what are the key challenges you anticipate in scaling up outside the U.S., particularly in markets like Japan where commercial launch is expected mid-2025, and how confident are you in achieving meaningful international revenue?
With the proposed tariffs potentially impacting gross margins by 50 to 75 basis points due to component suppliers in Mexico and China, what specific measures are you taking to mitigate this headwind, and are alternative supply chain strategies being considered to offset these impacts?
You mentioned incurring significant expenses related to FDA remediation efforts and DOJ subpoena activities, with remediation expenses expected to be approximately $15 million in 2025; can you elaborate on the nature of these regulatory issues, how they are affecting your operations, and when you expect these costs and impacts to subside?
Zio AT saw particular strength in the fourth quarter due to a competitor's disruption in the marketplace; how sustainable is this growth if the competitor resolves their issues, and what strategies are in place to maintain or accelerate Zio AT's growth in a more competitive environment?
Despite exiting 2024 with strong momentum and 24% year-over-year growth, along with multiple catalysts like record account openings, primary care channel momentum, and Epic integration, your 2025 guidance appears conservative; can you clarify what potential upsides are excluded from your guidance and what factors might limit growth in 2025?

Competitors

Competitors mentioned in the company's latest 10K filing.

Company	Description
BioTelemetry, Inc.	Acquired by Royal Philips, this company competes in providing remote cardiac monitoring technology and diagnostic services. They have developed patch-based cardiac monitors that have received FDA and foreign regulatory clearances.
Preventice Solutions, Inc.	Acquired by Boston Scientific, Inc., this company offers remote cardiac monitoring technology and diagnostic services. They have developed patch-based cardiac monitors that have received FDA and foreign regulatory clearances.
Bardy Diagnostics, Inc.	Acquired by Baxter International, Inc., this company provides remote cardiac monitoring technology and diagnostic services. They have developed patch-based cardiac monitors that have received FDA and foreign regulatory clearances.
GE Healthcare	This company sells traditional, 24-to-48-hour Holter monitors and competes in the remote cardiac monitoring market.
Philips Healthcare	This company sells traditional, 24-to-48-hour Holter monitors and competes in the remote cardiac monitoring market.
Spacelabs Healthcare Inc.	This company sells traditional, 24-to-48-hour Holter monitors and competes in the remote cardiac monitoring market.
Mortara Instrument, Inc.	Acquired by Hill-Rom Holdings, Inc., now part of Baxter International, Inc., this company sells traditional, 24-to-48-hour Holter monitors and competes in the remote cardiac monitoring market.
Welch Allyn Holdings, Inc.	Acquired by Hill-Rom Holdings, Inc., now part of Baxter International, Inc., this company sells traditional, 24-to-48-hour Holter monitors and competes in the remote cardiac monitoring market.
Apple Inc	This company has added capabilities on their watch platform to measure non-continuous ECG and to alert users to the potential presence of irregular heartbeats suggestive of asymptomatic Afib.
Fitbit	This company has added capabilities on their watch platform to measure non-continuous ECG and to alert users to the potential presence of irregular heartbeats suggestive of asymptomatic Afib.

Customer Concentration

Customer	Relationship	Segment	Details
Centers for Medicare & Medicaid Services (CMS)	Major payor of the company's Zio Services	All	Revenue: 24% of total revenue for 2024, 2023, and 2022. <br>Accounts Receivable: 15% (2024), 25% (2023).
One Commercial Customer	Commercial payor of the company's services	All	Accounts Receivable: 13% as of Dec 31, 2024.